<code id='D33E46507B'></code><style id='D33E46507B'></style>
    • <acronym id='D33E46507B'></acronym>
      <center id='D33E46507B'><center id='D33E46507B'><tfoot id='D33E46507B'></tfoot></center><abbr id='D33E46507B'><dir id='D33E46507B'><tfoot id='D33E46507B'></tfoot><noframes id='D33E46507B'>

    • <optgroup id='D33E46507B'><strike id='D33E46507B'><sup id='D33E46507B'></sup></strike><code id='D33E46507B'></code></optgroup>
        1. <b id='D33E46507B'><label id='D33E46507B'><select id='D33E46507B'><dt id='D33E46507B'><span id='D33E46507B'></span></dt></select></label></b><u id='D33E46507B'></u>
          <i id='D33E46507B'><strike id='D33E46507B'><tt id='D33E46507B'><pre id='D33E46507B'></pre></tt></strike></i>

          Home / comprehensive / focus

          focus


          focus

          author:explore    Page View:26
          Influenza A virions
          F. A. Murphy/CDC

          Vir Biotechnology said Thursday that a long-acting antibody drug designed to protect healthy individuals from influenza A failed to do so in a nearly 3,000-person clinical trial.

          Volunteers who received the highest dose of the drug, known as VIR-2482, were only 16% less likely than the placebo group to develop symptomatic influenza A infections, as defined by trial criteria, over a seven-month period. The difference was not statistically significant.

          advertisement

          The results are a setback in broader efforts to develop better protective measures against both seasonal and potential pandemic influenza strains. In the short term, Vir and outside experts hoped VIR-2482 could provide additional annual protection for at-risk groups like older adults, as flu vaccines are often only modestly effective.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In